At a glance
ClinicalIndex Comparison RecordPhase 1Active· 9 enrolled
Drug / intervention
Decitabine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Study of Tegavivint (BC-2059) in Patients With Relapsed and Refractory Leukemias
In Brief
A Phase 1 clinical trial evaluating Decitabine and Tegavivint for Recurrent Leukemia and Refractory Leukemia. Active but no longer recruiting, targeting 9 participants across 1 site.
Detailed Summary
This phase I trial is to find out the best dose and side effects of tegavivint in treating patients with leukemia that has come back (relapsed) or does not response to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tegavivint in combination with decitabine may help control the disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Leukemia, Refractory Leukemia
CountriesUnited States
Collaborators--
Timeline
Phase 1Active
202220232024202520262027
First PostedMay 2021
Enrollment StartSep 2021
TodayJul 2026
Primary CompletionFeb 2027
First PostedMay 5, 2021
Enrollment StartSep 27, 2021
Primary CompletionFeb 2, 2027
TodayJul 1, 2026
Enrollment to primary: 5.3 yearsPosted 5.2 years agoPrimary completion in 7 months
Interventions
Decitabinedrug
Given IV
Tegavivintdrug
Given IV